<DOC>
	<DOCNO>NCT01428141</DOCNO>
	<brief_summary>The purpose study investigate tolerability , safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) anti-tumor activity E7050 administer orally daily patient advance solid tumor gastric cancer .</brief_summary>
	<brief_title>A Phase I Study E7050 Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Inclusion Criteria 1 . Aged 20 less 75 year old time obtain informed consent . 2 . Histological cytological diagnosis solid tumor . 3 . Subjects progress treatment approve therapy standard effective therapy available . 4 . Adequate organ function . 5 . Subjects carryover effect prior therapy adverse drug reaction ( exclude alopecia ) may affect safety evaluation investigational drug . 6 . Performance Status ( PS ) 01 establish Eastern Cooperative Oncology Group ( ECOG ) . 7 . Expected survive 3 month longer start administration investigational drug . Exclusion Criteria 1 . Females pregnant breastfeeding . 2 . Brain metastasis clinical symptom require treatment . 3 . Serious complication disease history . 4 . Subjects take oral medication . 5 . Using antiplatelet/anticoagulant drug . 6 . Continuous use drug food strongly inhibit induce CYP3A4/5 CYP2D6 study period . 7 . Scheduled surgery study period . 8 . Known HIV , HBV HCV positive . 9 . Suffering psychotic disorder ( ) and/or unstable recurrent affective disorder ( ) evident use antipsychotic suicide attempt ( ) within approximately last 2 year . 10 . History drug alcohol dependency abuse within 2 year . 11 . Presence progressive central nervous system ( CNS ) disease , include degenerative CNS disease progressive tumor . 12 . Received investigational product device within 4 week administration .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Gastrointestinal Cancer</keyword>
</DOC>